Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity

Treatment with an agonist anti-OX40 antibody (aOX40) boosts anti-tumor immunity by providing costimulation and driving effector T cell responses. However, tumor-induced immune suppression contributes significantly to poor response rates to aOX40 therapy, thus combining aOX40 with other agents that r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Sturgill, Elizabeth R., Rolig, Annah S., Linch, Stefanie N., Mick, Courtney, Kasiewicz, Melissa J., Sun, Zhaoyu, Traber, Peter G., Shlevin, Harold, Redmond, William L.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7927986/
https://ncbi.nlm.nih.gov/pubmed/33717655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1892265
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados